Key terms
About ABEO
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABEO news
Apr 01
8:31am ET
Abeona Therapeutics announces employee inducement grants
Mar 18
7:34am ET
Abeona Therapeutics announces FDA completed PLI of its Ohio facility
Mar 18
7:34am ET
Abeona Therapeutics reports FY23 EPS ($2.53), consensus ($2.23)
Mar 05
7:34am ET
Abeona Therapeutics announces new employee inducement grants
Feb 01
7:37am ET
Abeona Therapeutics announces progress update on Pz-cel BLA
Jan 08
8:05am ET
Abeona Therapeutics announces $50M credit facility
No recent press releases are available for ABEO
ABEO Financials
Key terms
Ad Feedback
ABEO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABEO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
